This is the authors' abstract. We don't add key points for this paper.
In Reply: We would like to thank Rosenblatt and Johnson for their letter1 discussing our publication on the analgesic effect of adding liposomal bupivacaine to plain bupivacaine in the supraclavicular brachial plexus block.2 They have raised three issues on the article: differences on the quantity of bupivacaine used, interpretation of clinical significance, and off-label use.1 Below are our responses to the issues raised. Difference in Dose of Bupivacaine In this clinical trial, we investigated the analgesic efficacy of administering liposomal bupivacaine as it would be used in clinical practice. We agree that the difference in local anesthetic dose may be a confounding factor. However, it was not possible to have equal doses while maintaining an equal volume (20 ml) between groups. The drug release profile of liposomal bupivacaine—prolonged release with peak plasma bupivacaine levels at 48 h after brachial plexus block—is the key difference from plain bupivacaine.3 Therefore, the 150 mg bupivacaine from the liposomal bupivacaine (10 ml 1.33%) would have been released gradually. Single-shot regional nerve blocks using conventional local anesthetics provide a short duration of analgesia and are associated with rebound pain around 24 h after injection.4 Increasing the dose of plain bupivacaine is not likely to significantly extend the duration of analgesia and reduce rebound pain. In addition, using 200 mg plain bupivacaine may not be practical. First, the dose would exceed the maximum safety dose (2 mg/kg) for an average-sized adult (assuming body weight of 70 kg). Second, a volume of 40 ml plain bupivacaine (0.5%) would be required to deliver a dose of 200 mg, which is well above the usual volumes for ultrasound-guided supraclavicular brachial plexus blocks. Lower volumes should be used to reduce side effects including phrenic nerve palsy and diaphragmatic paralysis.5 Clinical Significance of the Observed Difference Although this was not the primary outcome, pain score with movement is important as early mobilization is associated with better outcomes.6 In our hospital, early mobilization is encouraged, and patients in usual postoperative care are not immobilized in a splint. We agree with the conclusion presented in the editorial in the same issue by Ilfeld and Sessler that the pain score differences on postoperative day 1 were clinically significant.7 As explained by Ilfeld and Sessler, the magnitude of the between-group differences (1.4 to 2.2), difference in the proportion of patients who experienced moderate or severe pain (28% in patients with liposomal bupivacaine vs. 68% in patients with only plain bupivacaine), and lower overall benefit of analgesia support this perspective. The decision on whether to use liposomal bupivacaine depends on circumstances such as patient factors, type of surgery, rehabilitation, and financial situation. Given the significant cost differences, liposomal bupivacaine may not be routinely used in publicly funded hospitals. However, it would be reasonable to consider using it for patients at a higher risk of having significant postoperative/rebound pain. In addition, cost may not be a significant issue for payers who can afford it (for example, private patients and/or those covered by insurance). While the cost of liposomal bupivacaine is currently high, this may change in the future. Off-label Use Off-label use is not uncommon in clinical practice. For example, off-label use of dexmedetomidine is common for pediatric patients.8 For regional nerve blocks, liposomal bupivacaine was initially approved for interscalene brachial plexus block, and this has now been expanded to include sciatic nerve block (popliteal) and adductor canal block. There is probably not much reason why liposomal bupivacaine cannot be used in the supraclavicular brachial plexus block if it is being used in the interscalene brachial plexus block. In our study, we showed that the combination of plain bupivacaine with liposomal bupivacaine was reliable in providing surgical anesthesia and was not associated with increased adverse effects. We agree that a clear explanation of potential risks and benefits should be explained to the patients. It is also important that the clinical benefit of liposomal bupivacaine is not overstated, given that there was no difference in pain intensity by postoperative day 2 or differences in oxycodone consumption, quality of recovery, sleep disturbance, and longer-term outcomes. The decision on whether the observed clinical benefit justifies the higher expenses would depend on the specific situation. Difference in opinion on when and whether it should be used is expected. Competing Interests The authors declare no competing interests.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: